Last updated: February 20, 2026
Reyvow (lasmiditan) is a prescription medication developed by Eli Lilly for the acute treatment of migraine. The supply chain involves several key components: active pharmaceutical ingredient (API) manufacturers, formulation and finished product producers, and distribution partners.
Key API Suppliers for Reyvow
Eli Lilly sources the lasmiditan API from specialized manufacturers. While the exact suppliers are confidential, general industry trends and disclosures point to certain pharmaceutical APIs vendors.
| Supplier Type |
Noted or Likely Suppliers |
Notes |
| API Manufacturers |
Multiple pharmaceutical API producers |
Lasmiditan synthesis involves complex multi-step processes typically performed by CDMOs (Contract Development and Manufacturing Organizations). Specific supplier identities are undisclosed publicly. |
| Contract Organizations |
WuXi STA, Zhejiang Huahai Pharmaceutical, Lonza |
These organizations are known for synthesizing complex APIs and have the capacity to produce lasmiditan at scale. |
Note: Public filings and patent literature do not explicitly identify the international API suppliers for Reyvow. Most pharmaceutical companies maintain confidentiality around suppliers until supply agreements are completed or disclosed in specific filings.
Formulation and Finished Product Manufacturing
Eli Lilly manages or outsources manufacturing of the final Reyvow tablets. The production facilities are compliant with Good Manufacturing Practices (GMP) and are located in multiple regions.
| Manufacturer Type |
Key Facilities |
Notes |
| Eli Lilly-operated |
Several facilities globally |
Eli Lilly directly oversees production at some sites in the United States and Europe. |
| Contract Manufacturing |
Contract manufacturers in the US and Europe |
Multiple firms contract with Lilly to produce tablets, often involving formulation, compression, coating, and packaging processes. |
Distribution Partners
Reyvow is distributed through a network comprising wholesale distributors, pharmacy chains, and specialty pharmacies. Major distributors include McKesson, Cardinal Health, and AmerisourceBergen.
| Distributor Type |
Noted Distributors |
Role |
| Wholesale Distributors |
McKesson, Cardinal Health, AmerisourceBergen |
Distribute to retail pharmacies and hospitals. |
| Specialty Pharmacies |
CVS Specialty, Walgreens Specialty |
Provide access for patients with specific needs. |
Supply Chain Considerations
- Regulatory Compliance: Manufacturing facilities must adhere to FDA and EMA standards.
- Capacity Constraints: As Reyvow is a relatively new therapy, supply chain scaling continues to evolve.
- Intellectual Property: Patents on lasmiditan extend into the late 2030s, affecting generic development and potential supply.
Industry Trends Impacting Supply
- Growing demand for migraine treatments increases pressure on API and formulation supply chains.
- The complexity of lasmiditan synthesis limits the number of qualified suppliers, which could impact stability and pricing.
- Eli Lilly’s control over manufacturing sites reduces supply risk but concentrates production capabilities.
Summary
The primary suppliers for Reyvow’s API are believed to include established CDMOs like WuXi STA and Zhejiang Huahai Pharmaceutical. Finished product manufacturing occurs at Lilly-operated or contracted facilities in the US and Europe. Distribution relies on several major pharmaceutical distributors and specialty pharmacies.
Key Takeaways
- The exact suppliers of lasmiditan API are undisclosed but likely include major CDMOs such as WuXi STA.
- Eli Lilly manages or contracts multiple manufacturing and formulation facilities globally.
- Distribution involves top pharmaceutical wholesale distributors and specialty pharmacies.
- Supply chain constraints relate to complex API synthesis, capacity limitations, and patent protections.
- Demand for migraine treatments influences supply security and pricing dynamics.
FAQs
1. Who manufactures the API for Reyvow?
The specific API supplier for Reyvow (lasmiditan) remains confidential. Likely sources include CDMOs like WuXi STA and Zhejiang Huahai Pharmaceutical, known for producing complex APIs.
2. Does Eli Lilly produce Reyvow entirely in-house?
Eli Lilly oversees some manufacturing and potentially collaborates with external contract manufacturers for formulation and packaging.
3. Are there alternatives to Reyvow on the market?
Reyvow's unique mechanism ( serotonin 5-HT1F receptor agonist) means it doesn't have direct substitutes; other migraine medications include triptans and gepants.
4. How could supply chain issues affect Reyvow availability?
API synthesis complexity and capacity constraints could lead to shortages; patent protections limit generic competition, which might stabilize supply.
5. What regions are major distribution hubs for Reyvow?
The US, Europe, and selected global markets where Eli Lilly holds regulatory approvals are primary distribution points.
Citations
[1] Eli Lilly. (2022). Reyvow (lasmiditan) prescribing information.
[2] U.S. Food and Drug Administration. (2019). Reyvow (lasmiditan) approval notice.
[3] Phan, T. (2022). APIs and CDMOs in complex drug manufacturing. Pharmaceutical Technology.
